Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Choueiri on Overall Findings of the CABOSUN Trial for RCC

February 4th 2017

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses overall findings of the phase II CABOSUN trial comparing cabozantanib (Cabometyx) versus sunitinib (Sutent) for patients with metastatic renal cell carcinoma.

FDA Grants Pembrolizumab Priority Review in Second-Line Bladder Cancer

February 4th 2017

The FDA has granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who progress following platinum-containing chemotherapy, according to Merck, the manufacturer of the PD-1 inhibitor.

FDA Grants Priority Review to Frontline Pembrolizumab for Urothelial Carcinoma

February 4th 2017

The FDA has granted a priority review to pembrolizumab as a treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma, according to Merck, the developer of the PD-1 inhibitor.

Dr. Lee on Immunotherapy's Future in RCC

February 3rd 2017

Chung-Han (Joe) Lee, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy in the treatment landscape of renal cell carcinoma.

Dr. Petrylak on FDA Approval of Nivolumab in Bladder Cancer

February 3rd 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from the phase II CheckMate-275 study.

Dr. Motzer on Nivolumab/Ipilimumab Activity in RCC

February 3rd 2017

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the data seen thus far with nivolumab plus ipilimumab in the treatment of patients with renal cell carcinoma.

FDA Approves Nivolumab for Urothelial Carcinoma

February 3rd 2017

The FDA has granted an accelerated approval to nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from a phase II CheckMate-275 study.

Pembrolizumab Prolongs Survival in Second-Line Urothelial Carcinoma

February 2nd 2017

Treatment with the PD-1 inhibitor pembrolizumab significantly prolonged overall survival over investigators’ choice of chemotherapy in patients with recurrent advanced urothelial carcinoma, according to results reported at the 19th European Cancer Congress.

Dr. Gong on Adverse Events of TKI VEGF-Directed Therapy in RCC

February 2nd 2017

Jun Gong, MD, fellow, City of Hope, discusses adverse events (AEs) associated with TKI/VEGF-directed therapy for patients with metastatic renal cell carcinoma (RCC).

Dr. Concepcion on Transition to Value-Based Model in Urology

February 1st 2017

Raoul Concepcion, MD, director of the Comprehensive Prostate Center, discusses the impending transition to a value-based model in urology.

Dr. Petrylak on Ongoing Investigations of Checkpoint Inhibition in Bladder Cancer

January 31st 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses immune checkpoint inhibitors that are currently being evaluated for the treatment of patients with bladder cancer.

Dr. Zhang on Challenges With Vaccines in Renal Cell Carcinoma

January 28th 2017

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses some of the challenges associated with administering vaccines to patients with renal cell carcinoma.

Dr. Sklar on Immunotherapy Potential in Bladder Cancer

January 28th 2017

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the potential of immunotherapy agents in the treatment of patients with bladder cancer.

Dr. Rosenberg on Frontline Immunotherapy Potential in Bladder Cancer

January 27th 2017

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential that immunotherapy has in the frontline setting for patients with bladder cancer.

Dr. Motzer on the Milestone of Immunotherapy in RCC

January 27th 2017

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the explosion of immunotherapy in the landscape of renal cell carcinoma (RCC).

Underreporting of Immunotherapy-Related AEs a Concern in RCC

January 24th 2017

Neeraj Agarwal, MD, discusses a trend of underreporting and underemphasizing toxicities associated with PD-1 inhibitors in the treatment of patients with renal cell carcinoma.

Dr. Pal on Preoperative Immunotherapy in Patients With RCC

January 24th 2017

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the potential with immunotherapy in the preoperative setting for patients with renal cell carcinoma.

Expert Discusses 2-Year Update of Pivotal Nivolumab RCC Trial

January 24th 2017

Elizabeth Plimack, MD, discusses updated data from the pivotal CheckMate-025 trial, which compared the use of nivolumab with everolimus in the treatment of patients with metastatic renal cell carcinoma.

Dr. Figlin on TKI Therapy Options in Renal Cell Carcinoma

January 23rd 2017

Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses tyrosine kinase inhibitors that he uses to treat patients with renal cell carcinoma.

Researcher Hopes Vaccines Can Improve Immunotherapy Outcomes in RCC

January 23rd 2017

Tian Zhang, MD, discusses the development of vaccines to treat patients with renal cell carcinoma.